.png)
ExplantLab, based in The Biosphere and spearheaded by David Langton, is revolutionising joint replacement technology through groundbreaking collaboration, resulting in better outcomes for patients.
As the only independent retrieval laboratory dedicated to analysing failed implants, ExplantLab is at the forefront of merging clinical practice with cutting-edge genetic testing to enhance patient outcomes.
David Langton, an orthopaedic surgeon turned innovator, founded ExplantLab to fill a critical void he identified in his field. “In my early days, when implants failed, there was no facility equipped to thoroughly analyse them,” Langton recalls. “This gap in the system inspired me to create ExplantLab.”
Partnering with Newcastle University, Langton’s team has developed techniques to scrutinise failed implants and formulate tailored solutions, marking a significant leap in orthopaedic research.
Central to their approach is a unique genetic test designed to match patients with the most compatible implant materials. Traditional joint replacements often use cobalt-chrome alloy, which may not suit every patient’s genetic profile. By aligning genetic information with implant materials, ExplantLab aims to reduce adverse reactions and prolong implant lifespan.
Collaboration is key to ExplantLab’s success. Langton’s partnership with Dr Raghu Sidaginamale, a trauma consultant at North Tees and Hartlepool NHS Trust, exemplifies this interdisciplinary approach.
Dr. Sidaginamale, who has a strong background in joint replacements, emphasises the value of their joint efforts. “The synergy between clinical insights and biochemical analysis at ExplantLab is truly remarkable,” he says. “We are combining our expertise to address the complex challenges of implant failure.”
The lab's findings reveal significant issues with certain knee implants. For example, polyethylene inserts used in around 10,000 devices have shown wear and instability. This wear can trigger allergic reactions in some patients, leading to further complications.
ExplantLab’s research aims to mitigate these problems through better material compatibility, showcasing the power of collaborative problem-solving.
ExplantLab’s work has broad implications beyond individual patient care. Improved implant performance not only enhances patient quality of life but also reduces the strain on healthcare systems and caregivers. By addressing these issues collaboratively, the lab is helping to alleviate the wider social and economic impacts of joint replacement surgery.
The collaboration extends beyond just Langton and Dr. Sidaginamale. ExplantLab integrates expertise from a diverse team of clinicians, biochemists, bioengineers, and AI specialists. This multidisciplinary approach is crucial for developing innovative solutions and driving forward the research.
“Our strength lies in our ability to bring together different fields of expertise,” Langton explains. “It’s the diversity of knowledge that enables us to develop new products and ideas.”
As Explant Lab prepares for global expansion, their commitment to collaboration remains central to their mission. The ongoing research and positive feedback from trials highlight the effectiveness of their approach. “We’re excited about the future and the potential to make a significant impact on joint replacement surgery worldwide,” Langton concludes.
By leveraging the power of interdisciplinary collaboration, Explant Lab is setting new standards in orthopaedic care and paving the way for more personalised and effective treatments.
John Seager, Estates Director, Newcastle Helix said: “This work exemplifies the power of collaboration in driving forward scientific innovation. We are very proud that Newcastle Helix has facilitated this relationship to grow, enabling the combination of expertise to address one of the complex challenges facing society at the moment and make a difference to people’s lives.”
Kommentare